Prominent Neutralizing Antibody Response Targeting the
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
25 03 2021
25 03 2021
Historique:
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
5
2
2021
Statut:
ppublish
Résumé
The severe death toll caused by the recent outbreak of Ebola virus disease reinforces the importance of developing ebolavirus prevention and treatment strategies. Here, we have explored the immunogenicity of a novel immunization regimen priming with vesicular stomatitis virus particles bearing Sudan Ebola virus (SUDV) glycoprotein (GP) that consists of GP1 & GP2 subunits and boosting with soluble SUDV GP in macaques, which developed robust neutralizing antibody (nAb) responses following immunizations. Moreover, EB46, a protective nAb isolated from one of the immune macaques, is found to target the GP1/GP2 interface, with GP-binding mode and neutralization mechanism similar to a number of ebolavirus nAbs from human and mouse, indicating that the ebolavirus GP1/GP2 interface is a common immunological target in different species. Importantly, selected immune macaque polyclonal sera showed nAb specificity similar to EB46 at substantial titers, suggesting that the GP1/GP2 interface region is a viable target for ebolavirus vaccine.
Identifiants
pubmed: 33536172
pii: JVI.01907-20
doi: 10.1128/JVI.01907-20
pmc: PMC8103683
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI136756
Pays : United States
Organisme : NIAID NIH HHS
ID : R41 AI147929
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI102766
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI134824
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI126587
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI109762
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142790
Pays : United States
Informations de copyright
Copyright © 2021 American Society for Microbiology.
Références
EMBO J. 2012 Apr 18;31(8):1947-60
pubmed: 22395071
Nature. 2014 Oct 2;514(7520):47-53
pubmed: 25171469
Immunity. 2018 Aug 21;49(2):363-374.e10
pubmed: 30029854
FEMS Microbiol Rev. 2016 Jul;40(4):494-519
pubmed: 27268907
Cell. 2016 Jan 14;164(1-2):258-268
pubmed: 26771495
N Engl J Med. 2016 Apr 28;374(17):1647-60
pubmed: 25830326
J Virol. 2015 Oct 14;90(1):266-78
pubmed: 26468533
J Virol. 2017 Oct 13;91(21):
pubmed: 28835491
J Struct Biol. 2007 Jan;157(1):38-46
pubmed: 16859925
J Virol. 1999 Jul;73(7):6024-30
pubmed: 10364354
Sci Transl Med. 2012 Jul 11;4(142):142ra96
pubmed: 22786681
J Struct Biol. 2009 Apr;166(1):95-102
pubmed: 19263523
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
mBio. 2016 Feb 23;7(1):e02154-15
pubmed: 26908579
N Engl J Med. 2017 Oct 12;377(15):1438-1447
pubmed: 29020589
J Immunol Methods. 2012 Dec 14;386(1-2):85-93
pubmed: 22989932
J Struct Biol. 2009 May;166(2):205-13
pubmed: 19374019
Cell. 2017 May 18;169(5):878-890.e15
pubmed: 28525755
Curr Opin Struct Biol. 2009 Aug;19(4):408-17
pubmed: 19559599
Cell. 2016 Jan 28;164(3):392-405
pubmed: 26806128
N Engl J Med. 2016 Aug 11;375(6):587-96
pubmed: 27509108
Virus Res. 2005 Oct;113(1):16-25
pubmed: 16139097
J Virol. 2010 Jan;84(1):163-75
pubmed: 19846533
Science. 2016 Mar 4;351(6277):1078-83
pubmed: 26912366
Vaccine. 2017 Jan 23;35(4):544-551
pubmed: 28024952
Cell Rep. 2016 May 17;15(7):1514-1526
pubmed: 27160900
Lancet Infect Dis. 2018 Jul;18(7):699-700
pubmed: 29627146
Science. 2005 Jun 10;308(5728):1643-5
pubmed: 15831716
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Methods Enzymol. 2003;374:461-91
pubmed: 14696385
J Infect Dis. 2018 Nov 22;218(suppl_5):S553-S564
pubmed: 29939318
Nature. 2008 Jul 10;454(7201):177-82
pubmed: 18615077
Bull World Health Organ. 1978;56(2):247-70
pubmed: 307455
Lancet. 2011 Mar 5;377(9768):849-62
pubmed: 21084112
Lancet. 1977 Mar 12;1(8011):571-3
pubmed: 65662
Front Immunol. 2014 Jun 02;5:250
pubmed: 24917864
Nat Struct Mol Biol. 2019 Mar;26(3):204-212
pubmed: 30833785
Sci Rep. 2016 Feb 10;6:20514
pubmed: 26861827
Trends Microbiol. 2016 Sep;24(9):684-686
pubmed: 27338027
Nat Struct Mol Biol. 2011 Nov 20;18(12):1424-7
pubmed: 22101933
J Struct Biol. 2003 Sep;143(3):185-200
pubmed: 14572474
Emerg Infect Dis. 2012 Sep;18(9):1480-3
pubmed: 22931687
Science. 2016 Oct 21;354(6310):350-354
pubmed: 27608667
Viruses. 2012 Apr;4(4):447-70
pubmed: 22590681
J Virol. 2015 Oct 14;90(1):279-91
pubmed: 26468532
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17182-7
pubmed: 25404321
J Immunol. 2016 May 1;196(9):3729-43
pubmed: 27001953
Science. 2016 Mar 18;351(6279):1339-42
pubmed: 26917593
J Infect Dis. 2019 Jan 9;219(3):415-419
pubmed: 30203042
Science. 2016 Mar 18;351(6279):1343-6
pubmed: 26917592
Nature. 2011 Sep 22;477(7365):466-70
pubmed: 21849977
Cell. 2017 May 18;169(5):891-904.e15
pubmed: 28525756
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Virology. 2013 Aug 1;442(2):97-100
pubmed: 23711383